Pelvic Floor Unit, Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.
Department of Gastroenterological Surgery, National Advisory Board of Incontinence and Pelvic Floor Health of Norway, University Hospital of North Norway, Tromsoe, Norway.
Colorectal Dis. 2024 May;26(5):968-973. doi: 10.1111/codi.16936. Epub 2024 Mar 11.
Sacral neuromodulation (SNM) is approved for the treatment of faecal incontinence (FI) in a two-stage technique. With standardized implantation, approximately 90% of patients undergo successful Stage I operation and proceed to a permanent implant (Stage II). The aim of this work was to explore the feasibility of SNM as a one-stage procedure and report the 24-week efficacy.
This study included patients diagnosed with idiopathic FI or FI due to an external anal sphincter defect ≤160° and one or more episodes of FI per week despite maximal conservative therapy. Patients were offered a one-stage procedure if a motor response of the external anal sphincter was achieved in three or more poles with at least one at ≤1.5 mA at lead placement. Patients were followed for 24 weeks. Their evaluation included the Wexner/St Mark's Incontinence Score, Faecal Incontinence Quality of Life score (FIQoL), a visual analogue scale (VAS) for assessing patient satisfaction and a bowel habit diary.
Seventy-three patients with a median age of 60 years (interquartile range 50-69 years) completed this prospective study. Episodes of FI were significantly reduced at the 24-week follow-up, from 13 (8-23) at baseline to 2 (0-5) (p-value = 0002). A ≥50% reduction in the number of FI episodes was achieved in 92% of participants. The Wexner score improved significantly from 16 (14-17) at baseline to 9 (5-13) (p-value < 0.001), and the St Mark's score improved significantly from 18 (16-20) to 11 (7-16) (p-value < 0.001). All domains in the FIQoL score and VAS for patient satisfaction improved significantly following the one-stage procedure.
A one-stage implantation procedure is feasible in selected patients with FI, significantly improving continence, quality of life and patient satisfaction after 24 weeks of follow-up.
骶神经调节(SNM)已获批用于治疗粪便失禁(FI)的两阶段技术。采用标准化植入方法,约 90%的患者成功完成第一阶段手术,并进行永久性植入(第二阶段)。本研究旨在探讨 SNM 作为一种一阶段手术的可行性,并报告 24 周的疗效。
本研究纳入了诊断为特发性 FI 或因外部肛门括约肌缺陷≤160°且每周至少发生一次 FI 的患者,且经过最大程度的保守治疗后仍未得到改善。如果在导联放置时,外部肛门括约肌的运动反应达到三个或更多导联,并且至少有一个导联的电流强度≤1.5mA,则为患者提供一阶段手术。患者随访 24 周。他们的评估包括 Wexner/St Mark 失禁评分、粪便失禁生活质量评分(FIQoL)、评估患者满意度的视觉模拟量表(VAS)和排便习惯日记。
73 名中位年龄为 60 岁(四分位间距 50-69 岁)的患者完成了这项前瞻性研究。在 24 周的随访中,FI 发作次数明显减少,从基线时的 13 次(8-23 次)减少到 2 次(0-5 次)(p 值=0.002)。92%的参与者FI 发作次数减少了≥50%。Wexner 评分从基线时的 16 分(14-17 分)显著改善至 9 分(5-13 分)(p 值<0.001),St Mark 评分从 18 分(16-20 分)显著改善至 11 分(7-16 分)(p 值<0.001)。FIQoL 评分和患者满意度的 VAS 所有领域在一阶段手术后均显著改善。
在选择的 FI 患者中,一阶段植入程序是可行的,在 24 周的随访后,显著改善了患者的控便能力、生活质量和满意度。